Overview of Fluvoxamine Teva

Quick Facts

Property	Description
Active Ingredient	Fluvoxamine (as maleate salt)
Form	Tablets (Immediate-release or Film-coated)
Pharmacological Class	Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose	Supports neurochemical balance in the brain
Origin	Synthetic Compound

What Type of Medicine is Fluvoxamine Teva?

Fluvoxamine Teva is a prescription-only oral medication defined by its active pharmaceutical ingredient, Fluvoxamine. This substance is categorized within the pharmacological class of Selective Serotonin Reuptake Inhibitors (SSRIs) and functions as a psychotropic agent. Fluvoxamine Teva, specifically, is a branded generic product from Teva Pharmaceuticals, which ensures a consistent formulation of the INN Fluvoxamine maleate. Its function is clinically recognized for helping to modulate central nervous system (CNS) activity and supporting mental health stability.

Composition and Delivery Form

The active compound, Fluvoxamine, is a purely synthetic entity, chemically manufactured rather than being derived from natural sources. Fluvoxamine Teva is supplied as a single active ingredient product in the form of film-coated tablets or extended-release capsules for oral use. The tablet's construction, composed of Fluvoxamine maleate and pharmaceutical excipients, provides a standardized and precise delivery method necessary for maintaining stable drug levels. The primary role of an SSRI is to increase the amount of the neurotransmitter serotonin available in the brain.

Fluvoxamine: A Selective Serotonin Modulator

The fundamental mechanism of effect of Fluvoxamine is selective serotonin reuptake inhibition. This action involves blocking the reabsorption of the neurotransmitter serotonin by nerve cells. By inhibiting this reuptake process, Fluvoxamine promotes a sustained increase in the concentration of available serotonin. This modulation of the serotonin environment is the central action intended to help support a stable neurochemical balance within the CNS.

What side effects are possible with Fluvoxamine Teva?

Possible Side Effects and Safety Information

Fluvoxamine's safety profile is documented by government regulatory bodies, classifying potential effects by frequency and the body system affected. Adverse reactions are grouped into categories such as Very Common, Common, Uncommon, and Rare.

Regulatory documents list the most common (Very Common) adverse reactions, which include nausea, somnolence (drowsiness), insomnia, asthenia (weakness), nervousness, dyspepsia (indigestion), abnormal ejaculation, and excessive sweating (hyperhidrosis). Common effects further include anxiety, dizziness, constipation, dry mouth, headache, and decreased libido.

Serious Adverse Reactions and Key Warnings

The prescribing information highlights the potential for rare but serious adverse reactions. The medication carries a high-level Boxed Warning regarding the increased risk of suicidal thoughts and behavior (suicidality) in children, adolescents, and young adults (up to age 24) when treated for certain psychiatric conditions. A potentially life-threatening condition, Serotonin Syndrome, is documented as a risk, especially during treatment initiation or dose increase, or when used with other serotonergic agents. Other serious safety concerns include the risk of Abnormal Bleeding and the potential to precipitate Angle-Closure Glaucoma.

Population and Time-Related Safety

Specific safety considerations are noted for certain groups. Older adults may be at increased risk for developing Hyponatremia (low blood sodium levels). Caution is advised in patients with hepatic impairment due to potential reductions in drug clearance. Safety patterns related to time include the observation that discontinuation may lead to symptoms such as dizziness, sensory disturbances, insomnia, and anxiety. Furthermore, the use of Fluvoxamine is restricted with certain other medications, such as Thioridazine and Tizanidine, due to drug interaction safety concerns outlined in official labels.

Overdose and Emergency Response

Fluvoxamine Teva Overdose and when to seek help

Overdose Scope

Element	Regulatory Statement
Documented Manifestations	Official labeling documents presentations including agitation, confusion, drowsiness, tremor, shivering, nausea, vomiting, and changes in heart rate.
Life-Threatening Outcomes	Severe overdosage may lead to seizures, loss of consciousness (coma), and, rarely, heart arrest or cardiac conduction abnormalities.

Emergency Actions and Management

Classification Aspect	Regulatory Statement
Immediate Help Required	Call emergency services immediately if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened. Otherwise, contact a poison control center for guidance.
Antidote Information	No specific treatment to reverse the effects of fluvoxamine is known to exist.

Official Overdose Statements

Management involves general measures employed in the treatment of overdosage and symptomatic supportive care for the presenting clinical effects.
The overdose profile is focused on symptoms affecting the Central Nervous System, Cardiovascular System, and Gastrointestinal System.

Connection to the overall overdose profile: The regulatory documents define the overdose profile through documented clinical manifestations affecting the CNS and cardiovascular systems, highlighting that serious outcomes like seizures and coma are possible. This profile is linked directly to emergency-seeking conditions by mandating that individuals exhibiting specific severe symptoms, such as collapse or respiratory distress, require an immediate call to emergency services. Treatment guidance strictly adheres to general and supportive management, as no specific reversal agent is listed in the official labeling.

Therapeutic Uses of Fluvoxamine Teva

Fluvoxamine Teva is commonly used to help manage complex, chronic conditions that may significantly interfere with a patient's daily stability. Its primary application is centered on managing highly distressing and recurrent patterns of thought and behavior.

The established use for this medication is for Obsessive-Compulsive Disorder (OCD) and, in certain formulations, Social Anxiety Disorder. The medication is generally applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms become temporarily overwhelming.

Therapeutic Scope: Compulsive and Anxiety Spectrum Relief

This medication is used to address symptom clusters that include persistent, unwanted intrusive thoughts (obsessions) and the urge to perform repetitive, time-consuming ritualized actions (compulsions). It is also relevant for managing pronounced fear and avoidance in conditions such as Social Anxiety Disorder and Panic Disorder. Fluvoxamine Teva helps manage these symptoms, potentially assisting with a reduction in their intensity and frequency, and may be relevant for use in certain pediatric groups for managing OCD symptoms. This symptomatic support may assist with general day-to-day comfort and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Compulsive and Phobic Symptoms

Property	Description
Primary Focus	Obsessive-Compulsive Disorder and related Anxiety Disorders
Symptom Type	Intrusive thoughts, ritualized behaviors, and intense fear/avoidance
Typical Context	Management of chronic, recurrent, and functionally limiting symptoms
Benefit	Supports functional stability and helps ease the overall symptom burden

Eligibility and Restrictions for Use

Fluvoxamine Teva (fluvoxamine maleate) is a prescription medicine whose use is strictly governed by official regulatory eligibility rules defined by government health authorities.

Contraindications (Must Not Use)

Use is absolutely prohibited (contraindicated) for patients who have a known hypersensitivity to fluvoxamine or its ingredients. Fluvoxamine Teva must not be used concurrently with a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one. Co-administration is also contraindicated with certain other drugs, which may include tizanidine and pimozide, due to the risk of serious adverse effects.

Age- and Condition-Based Eligibility

Population Group	Eligibility Status (Regulatory)
Pediatric (Under 8 Years)	Use is not established for safety and efficacy.
Children/Adolescents (8–17 Years)	Use is established for specific indications (e.g., Obsessive-Compulsive Disorder).
Older Adults (Geriatric)	Use is permitted, but requires special caution and close monitoring due to potential for reduced drug clearance or hyponatremia.
Hepatic Impairment	Eligible with restriction; requires a lower starting dose and slower titration due to altered drug clearance.
Pregnancy	Use requires a risk/benefit decision due to potential complications, particularly if taken late in the third trimester.
Breastfeeding	Fluvoxamine is secreted into human milk; use is generally not recommended or requires careful assessment of risk to the infant.

Patients with unstable epilepsy or a history of mania are also flagged for restricted use and require close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fluvoxamine Teva is known to interact significantly with a number of medicinal products through two primary mechanisms: affecting serotonin levels and altering the metabolism of other drugs.

Serotonin and Related Risks

Fluvoxamine's effect on serotonin carries a risk of Serotonin Syndrome when combined with other serotonergic medicines. This includes Monoamine Oxidase Inhibitors (MAOIs), such as Phenelzine, Isocarboxazid, and Linezolid, which are strictly contraindicated. Other agents that increase serotonin, such as Triptans (for migraine), Lithium, Tramadol, and St. John's Wort, must be used with caution and require close monitoring.

Drug Metabolism (CYP450 Enzyme Inhibition)

Fluvoxamine is a potent inhibitor of the liver enzyme CYP1A2 and, to a lesser extent, CYP2C19 and CYP3A4. This can significantly increase the blood levels of medicines metabolized by these enzymes, leading to toxicity. Medicines whose doses must be managed include: Clozapine, Theophylline, Warfarin, and some Tricyclic Antidepressants (TCAs). Due to this enzyme inhibition, co-administration with Tizanidine, Pimozide, and Ramelteon is also generally contraindicated.

Bleeding Risk

There is an increased risk of bleeding when Fluvoxamine is used alongside other medicines that affect blood clotting, such as Warfarin, Aspirin, or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Mechanism of Action

Primary Action: Selective Serotonin Reuptake Inhibition

Fluvoxamine Teva functions as a selective serotonin reuptake inhibitor (SSRI). Its primary biological target is the Serotonin Transporter (SERT) protein, located on the presynaptic nerve terminals in the central nervous system. The compound binds selectively to the SERT, blocking the reabsorption (reuptake) of the neurotransmitter serotonin (5-HT). This mechanistic action leads to a rapid and measurable increase in the concentration of free serotonin within the synaptic cleft, the space between nerve cells.

Modulation of Central Serotonergic Pathways

The sustained increase in synaptic serotonin functions to alter signaling dynamics within specific neural pathways. This mechanism results in the modulation of activity in systems governed by serotonergic mediators. The enhanced signal transduction influences neuronal firing rates within central circuits and reduces the magnitude of downstream effects resulting from increased mediator activity, thereby defining the compound's pathway-specific effects on the central nervous system.

Dosage and Administration Information

How to Use Fluvoxamine Teva

Fluvoxamine Teva is an oral medication provided as Immediate-Release (IR) tablets and Extended-Release (CR) capsules. The administration protocol focuses on precise dosing, timing, and preparation to ensure proper use.

Dosing and Administration Principles

Feature	Administration Summary
Route & Preparation	Taken orally. Tablets and capsules must be swallowed whole with water. Extended-release capsules must not be crushed or chewed.
Timing in Relation to Meals	May be taken with or without food. Administration is typically recommended at bedtime to align with the standard dosing schedule.
Adult Dosing Regimens	Treatment is initiated at a low starting dose (e.g., 50 mg for IR or 100 mg for CR) and gradually increased. The maximum daily dose is 300 mg/day.
Frequency of Use	CR capsules are taken once daily. IR tablets are taken once daily for doses le 100 mg, but doses > 100 mg must be divided into two doses (twice daily), with the larger dose taken at bedtime.

Usage Patterns Over Time

Fluvoxamine Teva is intended for use as a long-term management plan for responding patients. The process of establishing the correct intake amount involves a slow, incremental titration of the initial dose, typically in 50 mg increments every four to seven days, until the lowest effective dose is determined.

For pediatric patients (8–17 years) and older adults or individuals with hepatic impairment, instructions mandate starting at a lower initial dose and following a slower titration schedule. When therapy is discontinued, a gradual dose reduction (tapering) process is required, rather than abrupt cessation of use.

Recent Clinical Evidence

Fluvoxamine Teva: Recent Clinical Evidence

Research evidence for Obsessive-Compulsive Disorder (OCD) is primarily based on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies included both adult patients and children and adolescents and monitored outcomes related to symptom intensity using specialized scales. Findings describe patterns where changes in symptom severity measures were reported in the study group compared to the placebo group. Comparative evidence is lacking to describe study outcomes when compared directly to all other agents, and there is limited information for long-term outcomes beyond the acute treatment phase.

The evidence base for Social Anxiety Disorder (SAD) was also evaluated in RCTs, which explored short-term symptom patterns and assessed patient-reported outcomes related to social fear and avoidance. Systematic reviews described patterns of symptomatic change that were observed in the study group compared to the control group. Observation periods in these trials were often intermediate-term, ranging up to 24 weeks, but very limited data are available from studies describing long-term symptom patterns.

In a separate research context, Fluvoxamine was studied for use in acute episodes associated with a COVID-19 diagnosis. This research, based on RCTs and Meta-analyses, monitored outcomes such as the frequency of clinical deterioration events in non-hospitalized adult patients. Findings were mixed; some systematic reviews reported the frequency of clinical deterioration events in the study group compared to the control group, but outcomes related to mortality risk were described as inconsistent. Research is ongoing in this area, and this is not a regulatory indication.

Overall, the evidence highlights what is known, but data for certain special populations, such as older adults or those with complex comorbid conditions, remain insufficient. Furthermore, the broader evidence landscape shows that many trials focused on short-term symptom patterns and had follow-up durations that were limited in length.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Fluvoxamine Teva (FAQ)

Q: Is Fluvoxamine Teva considered an addictive medication?

Fluvoxamine Teva is generally not classified as a controlled substance by regulatory bodies and is not associated with the same potential for abuse or addiction as controlled medications. However, the official prescribing information notes that treatment should be discontinued gradually under a healthcare provider's supervision, rather than abruptly stopped.

Q: What are the signs that Fluvoxamine Teva might not be the right medication for someone?

Regulatory documents advise patients and caregivers to monitor for signs that may require urgent medical attention. These symptoms include the emergence of suicidal thoughts or behavior, any signs of an allergic reaction, symptoms consistent with Serotonin Syndrome, or any abnormal bleeding. These concerns should be reported to a healthcare professional for guidance.

Q: Can Fluvoxamine Teva cause any issues with sexual function?

Yes, official prescribing information lists sexual side effects as possible adverse reactions when taking Fluvoxamine Teva. These effects can include a decreased libido (sexual desire) and abnormal ejaculation. Patients experiencing these concerns often discuss them with their healthcare providers.

Q: Is Fluvoxamine Teva available as a generic, and is the generic version the same as the brand name?

Fluvoxamine Teva is itself a branded generic product of the active ingredient, fluvoxamine maleate. Generic formulations are required to meet strict governmental quality and testing standards to demonstrate therapeutic equivalence to the reference product.

Q: Why do some people feel fatigued when they first start Fluvoxamine Teva?

Drowsiness (somnolence) and weakness (asthenia) are listed as very common adverse reactions in the official drug information. These effects are a known part of the drug’s profile, particularly when treatment is first initiated.

Q: Is it necessary to take Fluvoxamine Teva with food, or can it be taken on an empty stomach?

Regulatory instructions state that Fluvoxamine Teva may be taken with or without food. The flexibility allows for administration at a time specified by a healthcare provider.

Q: Can Fluvoxamine Teva make anxiety symptoms feel worse before they get better?

Anxiety, nervousness, and agitation are all listed as common side effects of Fluvoxamine Teva. Official guidance emphasizes the need to closely monitor symptoms, especially during the initial treatment period. Any sudden or concerning changes should be reviewed by a healthcare provider.

Q: How is Fluvoxamine Teva processed and eliminated from the body?

Fluvoxamine Teva is extensively broken down (metabolized) primarily by enzymes in the liver. Due to this process, official prescribing information notes that dosage adjustments may be necessary for individuals with hepatic (liver) impairment, due to the way the body breaks down the medication.

Q: Why do some medications, particularly those affecting serotonin, require a waiting period before starting Fluvoxamine Teva?

Q: Does Fluvoxamine Teva cause weight gain or weight loss?

Official prescribing information notes that changes in appetite are listed as a possible adverse reaction. Since appetite changes can potentially lead to either weight gain or weight loss, this is a factor that may be monitored during ongoing treatment.

Q: Can Fluvoxamine Teva affect sleep patterns, like causing insomnia or vivid dreams?

Insomnia (difficulty sleeping) and somnolence (drowsiness) are listed as very common side effects. Abnormal or intense dreams are also listed in the adverse reaction profile, sometimes noted in relation to discontinuing the medication.

Q: How often do people generally need check-ups while on Fluvoxamine Teva?

Regulatory medication guides stress the importance of keeping all scheduled follow-up visits with the healthcare provider. Close monitoring is particularly necessary when a patient is initiating treatment or when the dosage is being adjusted, to observe for any clinical changes or side effects.

Q: Is there a maximum recommended duration for taking Fluvoxamine Teva?

Clinical trials systematically evaluate the drug's effectiveness over defined periods. For patients who respond well, the official information suggests that the long-term usefulness of the medication is typically re-evaluated by a healthcare provider on a periodic basis.

Q: Are there specific symptoms that warrant calling a doctor immediately while on Fluvoxamine Teva?

Official documentation advises that symptoms such as signs of Serotonin Syndrome (e.g., agitation, hallucinations, rapid heart rate), a severe allergic reaction, unusual eye pain or visual changes, or signs of abnormal bleeding should be immediately reported to a healthcare professional.

Q: Does alcohol consumption present a significant risk while taking Fluvoxamine Teva?

Official product information suggests that alcohol consumption should be avoided while using Fluvoxamine Teva. This is due to the potential for alcohol to intensify or add to the central nervous system side effects of the medication, such as dizziness or drowsiness.

Q: Does Fluvoxamine Teva interact with nicotine or smoking?

Yes, official labeling indicates that smoking can potentially affect the metabolism and blood levels of Fluvoxamine Teva. Fluvoxamine is a potent inhibitor of the CYP1A2 enzyme, which smoking can affect. Dose adjustments may be considered by a healthcare provider for patients who smoke.

Q: What are the potential effects of Fluvoxamine Teva on memory or concentration?

The official product information includes a caution that Fluvoxamine may interfere with a person’s ability to perform tasks requiring mental alertness, such as driving or operating machinery. These potential effects may be discussed with a healthcare provider.

Q: How do doctors typically determine the best time of day to take Fluvoxamine Teva?

The medication is typically recommended to be taken at bedtime. This timing is generally advised to help manage or minimize the impact of common side effects like drowsiness (somnolence). If the immediate-release dose is divided into two, the larger portion is also taken at bedtime.

Q: What is the mechanism by which Fluvoxamine Teva is thought to treat social anxiety disorder?

Fluvoxamine Teva’s mechanism of effect is the selective inhibition of serotonin reuptake (SSRI), which increases the availability of serotonin in the brain. This action is understood to modulate central nervous system activity, supporting neurochemical balance, which is the intended therapeutic effect for conditions like Social Anxiety Disorder.

Q: Do older adults typically react differently to Fluvoxamine Teva compared to younger people?

Yes, official information notes that older adults may require special caution. They may need a lower initial dose and a slower rate of dose increase due to potential reduced drug clearance. They may also be at an increased risk for certain side effects, such as low blood sodium levels (hyponatremia).

Q: What kinds of tests or screenings are needed before starting Fluvoxamine Teva?

Before starting treatment, healthcare providers are advised to screen patients for a history of certain medical conditions, such as mania, unstable epilepsy, and Angle-Closure Glaucoma. Depending on the patient's condition, other screenings, such as blood tests for sodium levels, may also be considered by the healthcare provider.

Q: Is it normal to feel a bit more anxious or restless in the first week of taking Fluvoxamine Teva?

Common side effects like nervousness, agitation, and anxiety are noted in the official prescribing information. While these can occur early in treatment, any significant or sudden worsening of emotional symptoms should be reviewed by a healthcare provider.

Q: Are there any long-term side effects associated with taking Fluvoxamine Teva?

The official prescribing information lists known adverse effects and includes a caution to periodically re-evaluate the drug's continued usefulness for patients on extended treatment. Patients often discuss any persistent or new side effects with their healthcare provider during routine follow-ups.

Q: What are the possible mental or emotional changes that occur while taking Fluvoxamine Teva?

Official documents note emotional changes such as nervousness, anxiety, and agitation. The drug also carries a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in young adults and adolescents. It is standard for all emotional changes to be reported during follow-up appointments.

How should Fluvoxamine Teva be stored and disposed of?

Storage and Disposal of Fluvoxamine Teva

The storage and disposal of Fluvoxamine maleate tablets must strictly follow regulatory documentation to ensure product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at room temperature (15^circ to 30^circC or 59^circ to 86^circF).
Protection	Keep the tablets away from high humidity.
Container	The bottle must be kept closed tightly.
Child Safety	Store the medicine out of the reach and sight of children.

Disposal Instructions

Unused or expired Fluvoxamine maleate must be disposed of according to local regulations. Regulatory standards prohibit discarding the medicine via wastewater or typical household waste to prevent environmental contamination.

Fluvoxamine Teva